| Similar Articles |
|---|
 |
The Motley Fool
August 30, 2004
W.D. Crotty |
Warning Bells for Specialty Pharmacy? Accredo Health lowers earnings guidance for 2005.   |
The Motley Fool
February 28, 2005
Brian Gorman |
Medco Covers Its Bases Medco's purchase of Accredo is a nod to future growth in biotech drug spending. |
BusinessWeek
March 7, 2005
Amy Barrett |
A Drug Company On Growth Hormones By adding Accredo to its portfolio, Medco gains a strong presence in the area of specialty drugs. Investors sent Medco's stock down slightly on news of the deal. But they give company chief David B. Snow Jr. credit for putting Medco in a position to capitalize on new opportunities. |
The Motley Fool
April 27, 2005
Brian Gorman |
Cautious on Medco Medco's earnings were respectable, but for now investors may want to step back. |
The Motley Fool
March 4, 2005
Tom Taulli |
In the Express Scripts Lane Express Scripts' strong results bring a much-needed lift to health-care investors. |
Managed Care
September 2005
John Carroll |
Plans Struggle for Control of Specialty Pharma Costs Biotech drugs are a quickly growing component of health plan budgets. Here are the latest management techniques. |
Managed Care
September 2006
Martin Sipkoff |
Specialty Pharmacy Grows As Cost-Control Option As the population ages, specialty pharmacy is becoming a unique, profitable, and invaluable delivery system. Plans are increasingly turning to specialty pharmacies to provide the expertise they lack. |
